A growing literature supports the safety and efficacy of active surveillance for patients with low-risk prostate cancer. However, the experience behind this literature is based almost entirely in academic centers, and prior reports have consistently found surveillance generally underused in most other settings.
1,2 Conversely, high-risk tumors have been undertreated with androgen deprivation treatment alone.
2,3 Recent trends in community-based practice patterns have not been well documented.